@article{f5e4bfea35be47be97921652ba0d49f5,
title = "Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de premi{\`e}re ligne du carcinome r{\'e}nal avanc{\'e} (aRCC) dans l{\textquoteright}{\'e}tude CheckMate 214 : suivi {\`a} 4 ans et analyse en sous-groupe des patients (pts) non n{\'e}phrectomis{\'e}s",
author = "L. Albiges and N. Tannir and M. Burotto and D. Mcdermott and E. Plimack and P. Barth{\'e}l{\'e}my and C. Porta and T. Powles and F. Donskov and S. George and C. Kollmannsberger and H. Gurney and M. Grimm and Y. Tomita and D. Castellano and B. Rini and T. Choueiri and {Shally Saggi}, S. and M. Mchenry and R. Motzer",
note = "Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",
year = "2020",
month = nov,
day = "1",
doi = "10.1016/j.purol.2020.07.155",
language = "Francese",
volume = "30",
pages = "785--786",
journal = "Progres en Urologie",
issn = "1166-7087",
publisher = "Elsevier Masson",
number = "13",
}